✦ LIBER ✦

Tu1122 Optimal Dosing of Mesalamine for Maintenance of Clinical Remission in Patients With Distal Ulcerative Colitis and Residual Endoscopic Activity: A Subgroup Analysis of a Double-Blind, Double-Dummy, Randomized, Controlled, Dose-Ranging Study

✍ Scribed by Kruis, Wolfgang; Greinwald, Roland; Mueller, Ralph

Book ID: 122700115
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 246 KB
Volume: 144
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(13)62838-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P206 - Which patient population profits

P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

✍ W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 51 KB

Direct comparison of two different mesal

Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: A double-blind, randomized study

✍ Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 2 views

Background: Mesalamine has been used as the first-line medication for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two different mesalamine formulations in the maintenance of remission in patients with UC. ## Methods: In a multicenter, double-blind, ran